Paper Title
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Pubmed ID
32317292
Date
2020/04/22
Member Group
SADaCC
Member Name
Mzodidi Tutuka